The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
Oncology · 2023 · 101 (1) · 69-76
DOI: 10.1159/000526964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 14.09.2022. Verfasst von Masashi Kasajima und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Predictors of the effectiveness of immune checkpoint inhibitor (ICI) monotherapy in previously treated patients with non-small cell lung cancer (NSCLC) remain ill-defined. We investigated whether the Glasgow prognostic score (GPS) could serve as such predictors.
Methods
Eighty patients treated with pembrolizumab or atezolizumab monotherapy as second- or subsequent-line therapy for NSCLC were retrospectively reviewed, and the associations between GPS, body mass index (BMI), and each of progression-free survival (PFS) and overall survival (OS) were assessed.
Results
The median follow-up period was 11.1 months. Patients with a BMI ≥20.4 kg/m2 had significantly longer PFS and OS (3.7 and 22.2 month, respectively) than did those with a BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
- School of Nursing, Kitasato University, Sagamihara, Japan.
- School of Allied Health Sciences, Kitasato University, Sagamihara, Japan.
- Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Zitieren
APA
Kasajima, M., Igawa, S., Manaka, H., Yamada, K., Akazawa, Y., Manabe, H., Yagami, Y., Yamamoto, H., Ito, H., Kaizuka, N., Nakahara, Y., Sato, T., Mitshufuji, H., Yokoba, M., Kubota, M., Sasaki, J., & Naoki, K. (2023). The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer. Oncology, 101(1), 69-76. https://doi.org/10.1159/000526964
Vancouver
Kasajima M, Igawa S, Manaka H, Yamada K, Akazawa Y, Manabe H, et al. The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer. Oncology. 2023;101(1):69-76. doi:10.1159/000526964
BibTeX
@article{Kasajima2023,
author = {Kasajima, Masashi and Igawa, Satoshi and Manaka, Hiroya and Yamada, Kaori and Akazawa, Yuki and Manabe, Hideaki and Yagami, Yuri and Yamamoto, Hiroki and Ito, Hiroki and Kaizuka, Nobuki and Nakahara, Yoshiro and Sato, Takashi and Mitshufuji, Hisashi and Yokoba, Masanori and Kubota, Masaru and Sasaki, Jiichiro and Naoki, Katsuhiko},
title = {The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer},
journal = {Oncology},
year = {2023},
volume = {101},
number = {1},
pages = {69--76},
doi = {10.1159/000526964}
}
EUVIMED